TrialCompass™ TCL
Back to trials
Enrolling by invitationPriority 4 · Lower priorityNCT07450040

Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This trial is testing tislelizumab (anti-PD-1) combined with chemotherapy and chidamide for patients with extranodal NK/T-cell lymphoma (ENKTL) at various stages of their disease. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States.

Who can join (key eligibility)

  • Age 18 Years to 70 Years years
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

What is ENKTL?

Plain-language overview of ENKTL plus all curated trials for this subtype.

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma

NCT07450040

Status: Enrolling by invitation | Priority: Lower

Plain-language summary

This trial is testing tislelizumab (anti-PD-1) combined with chemotherapy and chidamide for patients with extranodal NK/T-cell lymphoma (ENKTL) at various stages of their disease. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States.

Who can join

  • Age 18 Years to 70 Years years
  • Must be well enough for treatment (adequate performance status)

What's being tested

Drugs / treatments:

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 60 patients

Primary endpoint: ORR

Ages: 18 Years to 70 Years

Start date: 2024-09-12 | Est. completion: 2027-12-31

Locations

0 US sites · 1 total

Contact

—

Sponsor: Eye & ENT Hospital of Fudan University (OTHER)

Tags

ENKTL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07450040

Prepared using TrialCompass (trialcompass.com) on August 18, 2026. For informational purposes only. Always discuss with your healthcare team.